JNJ-79635322 for hard-to-treat myeloma or amyloidosis
Treatments studied
Part of Blood & lymphatic, Cancer, Heart & circulation, Hormones & metabolism, Immune system & allergy clinical trials.
This Phase 1 study tests how safe and how well JNJ-79635322 works in people with multiple myeloma that has come back or is resistant to treatment, or AL amyloidosis that has already been treated. It may help by targeting cancer cells and abnormal proteins driving these diseases.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have been diagnosed with multiple myeloma (MM) or with AL amyloidosis confirmed by tissue testing (a biopsy).
- Your disease must be “relapsed” or “refractory,” meaning it came back or did not respond, and you’ve had multiple prior treatment types (and likely at least 3 prior treatment lines for MM or AL amyloidosis).
- You must have measurable disease at screening (based on specific blood/urine protein levels or scans showing active disease).
- Your general health/activity level must be ECOG 0 or 1 (able to carry out daily activities with little or no restriction).
- For MM, you must NOT have certain exclusions such as cancer in the brain/spinal fluid, plasma cell leukemia, or POEMS; for AL amyloidosis, you must NOT have CNS involvement, non-AL amyloidosis (like ATTR), or POEMS.
- Your heart function must be adequate: left ventricular ejection fraction (LVEF) 45% or higher (for AL amyloidosis patients).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests an experimental drug for multiple myeloma that has come back or not responded to at least three previous treatments. It aims to see if the drug can help people whose cancer has progressed despite prior therapies including a proteasome inhibitor, an immunomodulatory drug, and an anti-CD38 antibody.
This trial tests an anti-CD38 antibody drug that is “linked” to a cancer-killing payload (an antibody-drug conjugate) in people with multiple myeloma that has returned or did not respond to standard treatments. It is mainly looking at safety first, and also whether it can reduce myeloma in heavily pre-treated patients.
This study tests a new gene therapy for people with multiple myeloma that has come back or stopped responding to at least 3 prior treatments. The therapy is designed to help your immune system fight the cancer cells more effectively.
This study tests a new drug called elranatamab for people with multiple myeloma that has come back or not responded to previous treatments. Elranatamab is a type of immunotherapy that targets a protein on myeloma cells to help your immune system fight the cancer.
This trial tests a new drug combined with other medicines for people with multiple myeloma, a related condition called AL amyloidosis, or high-risk smoldering multiple myeloma. It aims to see if the combination is safe and effective.
This Phase 1/2 study tests AZD0120 in people with multiple myeloma that has come back or is not responding to treatment. It may help by targeting the myeloma cells after you’ve already tried several standard therapies.
Hear when a new Relapsed or Refractory Multiple Myeloma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.